Firefly Neuroscience Unveils AI-Powered Brain Age Biomarker Using FDA-Cleared BNA™ Platform

Breakthrough in Brain Age Assessment

Firefly Neuroscience, Inc. (NASDAQ: AIFF), an AI-driven healthcare company, has announced a significant advancement in brain health research. The company has developed a method to assess a patient's cognitive brain age using its FDA-cleared Brain Network Analytics (BNA™) technology platform 1

1

Innovative Use of EEG Data

Gil Issachar, Chief Technology Officer of Firefly, presented the groundbreaking findings at AD/PD 2024. The BNA™ system utilizes both Resting EEG and Cognitive EEG (ERP) data to estimate the biological age of a person's brain. This marks the first instance where cognitive data measured by ERP has been successfully used for assessing biological brain age 1

1

Potential Impact on Dementia and Alzheimer's Detection

The technology has shown promise in identifying disparities between brain age and chronological age, which could serve as a valuable risk factor for dementia. By enabling the measurement of brain age through EEG, Firefly is potentially opening doors to a proactive and scalable approach for early screening and monitoring of Alzheimer's patients 1

1

AI-Powered Brain Health Solutions

Firefly's BNA™ technology was developed using artificial intelligence and machine learning, leveraging a comprehensive database of over 17,000 patients representing twelve disorders and clinically normal patients. The system, when used in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function, enhancing their ability to accurately diagnose mental and cognitive disorders and evaluate optimal therapies 1

1

Related Stories

Firefly Neuroscience Unveils AI-Powered CLEAR Platform, Boosting EEG Technology with Nvidia Partnership

Firefly Neuroscience's AI-Powered EEG Analytics Show Promise in Drug Development and Neuropsychiatric Care

Firefly Neuroscience Secures $12.4 Million Financing to Advance AI-Powered Brain Health Technology

Firefly Neuroscience stock surges 47.7% on AI-powered ADHD subtype diagnosis breakthrough

Market Response and Future Prospects

The announcement of this breakthrough has had a significant impact on Firefly Neuroscience's market performance. The company's shares doubled to $3.90 following the news, reflecting investor confidence in the potential of the BNA™ platform 2

2

Commercialization and Industry Impact

Firefly is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use. This move could potentially revolutionize diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD 1

1